Severe ischemia following treatment with rituximab in a patient with mixed connective tissue disease: An unusual complication

Lupus

Volumn 19, Issue 8, 2010, Pages 1005-1006

  Vela, P ^a   Sivera, F ^a   Batlle Gualda, E ^a   Mayor, M ^b   Garcia Manzanares A ^c   Pascual, E ^a  

^a UNIVERSITY OF ALICANTE   (Spain)

^b HOSPITAL RAFAEL MÉNDEZ   (Spain)

^c HOSPITAL DE TORREVIEJA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTINUCLEAR ANTIBODY; BOSENTAN; DIPHENHYDRAMINE; ILOPROST; METHYLPREDNISOLONE; PARACETAMOL; RITUXIMAB; SILDENAFIL; MONOCLONAL ANTIBODY;

ADULT; ANTIBODY TITER; CASE REPORT; CLINICAL FEATURE; DISEASE SEVERITY; FEMALE; HUMAN; ISCHEMIA; LABORATORY DIAGNOSIS; LETTER; MIXED CONNECTIVE TISSUE DISEASE; MYOPATHY; PRIORITY JOURNAL; RAYNAUD PHENOMENON; SALIVARY GLAND BIOPSY; SCLERODERMA; SERUM SICKNESS; TREATMENT OUTCOME; ADOLESCENT; CHEMICALLY INDUCED; COMPLICATION;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; FEMALE; HUMANS; ISCHEMIA; MIXED CONNECTIVE TISSUE DISEASE;

EID: 77954076866     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203310369145     Document Type: Letter

References (10)

1. Garcia-Carrasco M., Mendoza-Pinto C., Sandoval-Cruz M., et al. Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients. Lupus 2010 ; 19: 213-219.
2. Devauchelle-Pensec V., Pennec Y., Morvan J., et al. Improvement of Sögren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum 2007 ; 57: 310-317.
3. McGonagle D., Tan AL, Madden J., et al. Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab. Rheumatology (Oxford) 2008 ; 47: 552-553.
4. Haroon M., O'Gradaigh D., Foley-Nolan D. A case of Raynaud's phenomenon in mixed connective tissue disease responding to rituximab therapy. Rheumatology 2007 ; 46: 718-719.
5. Eisenberg R. Update on rituximab. Ann Rheum Dis 2005 ; 64: iv55 - iv57.
6. D'Arcy CA, Mannik M. Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab). Arthritis Rheum 2001 ; 44: 1717-1718.
7. Hellerstedt B., Ahmed A. Delayed-type hypersensitivity reaction or serum sickness after rituximab treatment. Ann Oncol 2003 ; 14: 1792.
8. Todd DJ, Helfgott SM Serum sickness following treatment with rituximab. J Rheumatol 2007 ; 34: 430-433.
9. Finger E., Scheinberg M. Development of serum sickness-like symptoms after rituximab infusion in two patients with severe hypergammaglobulinemia. J Clin Rheumatol 2007 ; 13: 94-95.
10. Emery P., Fleischmann R., Filipowicz-Sosnowska A., et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006 ; 54: 1390-1400.